PEG-Intron: Phase II data; Under review in U.S. and EU

ENZN partner Schering-Plough Corp. (SGP, Madison, N.J.) presented results of an open label Phase II dose-ranging study of PEG-Intron combined with its

Read the full 227 word article

How to gain access

Continue reading with a
two-week free trial.